Private practice

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

Retrieved on: 
Wednesday, April 3, 2024
Principal, Harvard Medical School, Alpern, Public, Public health, FICS, Private practice, Telecanthus, Patient, DED, MPH, Therapy, FACS, Frustration, Ophthalmology, Pharmaceutical industry

“Dr.

Key Points: 
  • “Dr.
  • Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions.
  • “Dr.
  • He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.

Cegedim Full year 2023 results: Revenue and recurring operating income both up

Retrieved on: 
Wednesday, March 27, 2024
Cloud, Automation, Certification, Health, HR, BPO, Software as a service, Growth, Allianz, Webcast, Private practice, Pharmacy, Data, Artificial intelligence, Acquisition, IMS Health, PDP, Marketing, Bank statement, IMS, P&L, Investment, Lawyer, Supreme court, Depreciation, Audit committee, Renting

The division’s recurring operating income climbed 33%, bolstered mainly by outsourcing for HR departments, which is riding a wave of management process automation.

Key Points: 
  • The division’s recurring operating income climbed 33%, bolstered mainly by outsourcing for HR departments, which is riding a wave of management process automation.
  • Sales to insurers posted positive recurring operating income, up slightly, despite the costs of launching the Allianz contract.
  • 2023 recurring operating income was a €4.5 million loss, €1.1 million higher than the loss in 2022.
  • Visiodent generated revenue of c.€10 million in 2023 and will begin contributing to Cegedim Group’s consolidation scope on March 1, 2024.

Senior SEC leader Jennifer Zepralka joins Mayer Brown

Retrieved on: 
Monday, April 8, 2024
House, Mayer Brown, Partnership, Private practice, Investment company, Speaker, Public policy, Policy, Disclosure, Small business, PKWN, Division, Corporate governance, International law, Regulation

WASHINGTON, April 8, 2024 /PRNewswire/ -- Mayer Brown announced that Jennifer Zepralka has joined the firm's Public Companies & Corporate Governance practice as a partner. She joins the firm from the SEC's Division of Corporation Finance, where she served as chief of the Office of Small Business Policy since 2018.

Key Points: 
  • WASHINGTON, April 8, 2024 /PRNewswire/ -- Mayer Brown announced that Jennifer Zepralka has joined the firm's Public Companies & Corporate Governance practice as a partner.
  • "We're very pleased to welcome Jennifer to our firm," said Jon Van Gorp, chair of Mayer Brown.
  • Mayer Brown is a global services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England & Wales), Mayer Brown (a Hong Kong partnership) and Tauil & Chequer Advogados (a Brazilian law partnership) and non-legal service providers, which provide consultancy services (collectively, the "Mayer Brown Practices").
  • "Mayer Brown" and the Mayer Brown logo are the trademarks of Mayer Brown.

ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease

Retrieved on: 
Wednesday, March 20, 2024
Oculoplastics, Patient, Private practice, Webcast, TED, Cohort, Standard of care, NEJM, MD, Graves' ophthalmopathy, Hyperglycemia, Safety, Huber loss, Orbital, Medical device

LOS ANGELES, March 20, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in thyroid eye disease (TED). Lonigutamab is a subcutaneously (SC) delivered humanized IgG1 monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R), a validated mechanism of action for the treatment for TED.

Key Points: 
  • There have been no reports of hyperglycemia or hearing impairment and no serious adverse events.
  • “It is very encouraging to see the results of subcutaneous administration of an anti-IGF-1R therapy.
  • The data shown suggest that there is a clinically meaningful response in patients as early as 3 weeks after a single subcutaneous dose of lonigutamab.
  • “It is important to note that this is preliminary data in a small group, however the positive results are highly promising.

Former Texas Assistant AG, US Trustee Trial Attorney Casey Roy Joins Austin Office of Ross, Smith & Binford, PC

Retrieved on: 
Tuesday, April 2, 2024
Legal, Professional Services, USTP, Private practice, Employment, Bankruptcy, Growth, Chapter Seven, Practice of law

Trustee trial attorney J. Casey Roy has joined the Austin office of the bankruptcy and mediation boutique Ross, Smith & Binford, PC .

Key Points: 
  • Trustee trial attorney J. Casey Roy has joined the Austin office of the bankruptcy and mediation boutique Ross, Smith & Binford, PC .
  • Trustee Program, Mr. Roy was responsible for oversight of Chapter 11 and Chapter 7 bankruptcy proceedings in the Western District of Texas.
  • “I worked with Jason when we were both at the Texas AG’s office and have followed the growth of Ross, Smith & Binford.
  • Prior to joining the USTP, Mr. Roy was an Assistant Attorney General at the Office of the Texas Attorney General in Austin as a member of the Bankruptcy and Collections Division.

Butterfield Appoints General Counsel Following Retirement

Retrieved on: 
Friday, March 15, 2024
Banking, Asset Management, Professional Services, Finance, American Express, NTB, Cayman Islands, General counsel, Private practice, Merrill (company), Bank, University, BSX, University College London, LLM, Senior, Multimedia, Slaughter

Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the appointment of Simon Des-Etages to General Counsel and Group Chief Legal Officer effective March 18, 2024.

Key Points: 
  • Butterfield & Son Limited ("Butterfield" or the "Bank") (BSX: NTB.BH; NYSE: NTB) today announced the appointment of Simon Des-Etages to General Counsel and Group Chief Legal Officer effective March 18, 2024.
  • Mr. Des-Etages succeeds Shaun Morris, who has served in the role for the last twelve years and made the decision to retire.
  • Mr Des-Etages then moved to Merrill Lynch, where he spent eight years working as a senior counsel in the Global Private Client Group.
  • He holds a Master of Laws (LLM) from University College London and a Bachelor of Laws from the University of Essex, UK.

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Optical, MAB, Drainage, Alcon, Private practice, Telecanthus, Patient, Bausch & Lomb, MBA, Ophthalmology, Optometry, FDA, Pharma, Pharmaceutical industry

Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.

Key Points: 
  • Dr. Fezza joins the MAB as Nordic Pharma prepares to launch a novel therapy for Dry Eye Disease, LACRIFILL® Canalicular Gel.
  • The FDA-cleared, cross-linked hyaluronic acid derivative LACRIFILL is intended to temporarily block tear drainage by the occlusion of the canalicular system.
  • “The entire U.S. Medical Advisory Board of Nordic Pharma is honored and delighted to welcome John Fezza, MD, a world class oculoplastic surgeon to our MAB,” said Eric Donnenfeld, MD, MAB Chair.
  • Nordic Pharma is committed to engaging ophthalmologists and optometrists in the early launch stages of LACRIFILL Canalicular Gel.

LOS ANGELES BUSINESS JOURNAL NAMES KAUFMAN LEGAL GROUP PARTNER JOSEPH GUARDARRAMA A DIVERSITY, EQUITY + INCLUSION TEAM LEADER

Retrieved on: 
Thursday, April 4, 2024
Election law, Private practice, Workplace, Los, Environment, Equity

LOS ANGELES, April 4, 2024 /PRNewswire/ -- Boutique political and government law firm Kaufman Legal Group announced today that Partner Joseph Guardarrama has been recognized by the Los Angeles Business Journal as a nominee for its Diversity, Equity + Inclusion Awards.

Key Points: 
  • LOS ANGELES, April 4, 2024 /PRNewswire/ -- Boutique political and government law firm Kaufman Legal Group announced today that Partner Joseph Guardarrama has been recognized by the Los Angeles Business Journal as a nominee for its Diversity, Equity + Inclusion Awards.
  • The awards honor diversity, inclusion, and equity champions in the Los Angeles region for their ongoing efforts to advance diversity and inclusion in the workplace and business leadership while simultaneously creating an inclusive environment that enables diversity and equity to thrive.
  • "We are so proud of Joe's recognition regarding his professional and community contributions and whole-hearted dedication to diversity, equity and inclusion," says Firm Principal Stephen Kaufman .
  • "This nomination not only reflects positively on Joe's achievements, but also speaks to the firm's ongoing commitment to fostering a diverse and inclusive workplace culture."

ResumeBuilder.com Survey Reveals 3 in 10 Workers Are Unlikely To Consider Jobs in States With IVF Restrictions

Retrieved on: 
Thursday, April 4, 2024
Fertilisation, Private practice, Employment, IVF, Ageing, Work, Legislation, Woman

SEATTLE, April 4, 2024 /PRNewswire-PRWeb/ -- ResumeBuilder.com, the premier resource for professional resume templates and career advice, has published a recent survey report investigating the impact of reproductive care public policies on workers' employment location preferences. The report also provides valuable insights into workers' attitudes toward legislation prohibiting in vitro fertilization. The survey collected responses from 1,250 employed adults in the United States.

Key Points: 
  • The survey collected responses from 1,250 employed adults in the United States.
  • "Public policies affecting women's health care are impacting where Americans want to live and work," says Stacie Haller.
  • Within this group, 51 percent say there is nothing that would make them more likely to consider a job offer in one of these states.
  • Among respondents, 30 percent report they are unlikely to consider a job offer in a state that has passed legislation effectively banning IVF.